The Behaviour of IL-6 and Its Soluble Receptor Complex during Different Waves of the COVID-19 Pandemic

Gaetano Di Spigna,Bianca Covelli,Maria Vargas,Roberta Di Caprio,Valentina Rubino,Carmine Iacovazzo,Filomena Napolitano,Giuseppe Servillo,Loredana Postiglione
DOI: https://doi.org/10.3390/life14070814
2024-06-27
Life
Abstract:In late December 2019, SARS-CoV-2 was identified as the cause of a new pneumonia (COVID-19), leading to a global pandemic declared by the WHO on 11 March 2020, with significant human, economic, and social costs. Although most COVID-19 cases are asymptomatic or mild, 14% progress to severe disease, and 5% develop critical illness with complications such as interstitial pneumonia, acute respiratory distress syndrome (ARDS), and multiple organ dysfunction syndrome (MODS). SARS-CoV-2 primarily targets the respiratory system but can affect multiple organs due to the widespread presence of angiotensin-converting enzyme 2 (ACE2) receptors, which the virus uses to enter cells. This broad distribution of ACE2 receptors means that SARS-CoV-2 infection can lead to cardiovascular, gastrointestinal, renal, hepatic, central nervous system, and ocular damage. The virus triggers the innate and adaptive immune systems, resulting in a massive cytokine release, known as a "cytokine storm", which is linked to tissue damage and poor outcomes in severe lung disease. Interleukin-6 (IL-6) is particularly important in this cytokine release, with elevated levels serving as a marker of severe COVID-19. IL-6 is a multifunctional cytokine with both anti-inflammatory and pro-inflammatory properties, acting through two main pathways: classical signalling and trans-signalling. Classical signalling involves IL-6 binding to its membrane-bound receptor IL-6R and then to the gp130 protein, while trans-signalling occurs when IL-6 binds to the soluble form of IL-6R (sIL-6R) and then to membrane-bound gp130 on cells that do not express IL-6R. The soluble form of gp130 (sgp130) can inhibit IL-6 trans-signalling by binding to sIL-6R, thereby preventing it from interacting with membrane-bound gp130. Given the central role of IL-6 in COVID-19 inflammation and its association with severe disease, we aimed to analyse the behaviour of IL-6 and its soluble receptor complex during different waves of the pandemic. This analysis could help determine whether IL-6 levels can serve as prognostic markers of disease severity.
biology
What problem does this paper attempt to address?
### Problems the paper attempts to solve This paper aims to analyze the behavior of interleukin - 6 (IL - 6) and its soluble receptor complex in different epidemic waves. Specifically, the researchers hope to solve the problems through the following aspects: 1. **Evaluate the changes of IL - 6 and its soluble receptor complex in different epidemic waves**: - The researchers explored the changing trends of these indicators in different waves by detecting the serum levels of IL - 6, sIL - 6R (soluble IL - 6 receptor) and sgp130 (soluble gp130) in COVID - 19 patients in different epidemic waves (WAVE I, WAVE II, WAVE III). 2. **Determine whether IL - 6 level can be used as a prognostic marker for disease severity**: - Early studies have found that IL - 6 level is closely related to the severity of COVID - 19. Therefore, the researchers hope to verify whether it can be used as a prognostic marker by analyzing the IL - 6 level in different epidemic waves, so as to help clinicians better predict the disease development of patients. 3. **Explore the influence of different variants on IL - 6 and its receptor complex**: - With the emergence of virus variants, especially the spread of the Delta variant, the researchers also evaluated the levels of IL - 6 and its receptor complex in patients infected with these variants to understand whether the variants will affect the changes of these inflammatory markers. ### Main findings 1. **Changes of IL - 6 level in different epidemic waves**: - In the first wave of the epidemic (WAVE I), the IL - 6 level in COVID - 19 patients increased significantly, approximately 400 times that of the healthy control group. - In the second wave of the epidemic (WAVE II), the IL - 6 level was still significantly higher than that of the healthy control group, but the increase was lower than that in the first wave. - In the third wave of the epidemic (WAVE III), the IL - 6 level continued to increase significantly, but the increase further decreased, approximately 50 times that of the healthy control group. 2. **Changes of sIL - 6R and sgp130 levels**: - sIL - 6R increased significantly in all waves, indicating a continuous inflammatory response. - sgp130 decreased significantly in the first wave of the epidemic, but gradually recovered to a level close to that of the healthy control group in subsequent waves. 3. **Influence of the Delta variant**: - In patients infected with the Delta variant, the levels of IL - 6 and sIL - 6R were still significantly increased, but the sgp130 level recovered to a level close to that of the healthy control group. ### Conclusion This study reveals the differences in the behavior of IL - 6 and its soluble receptor complex in different epidemic waves, and preliminarily verifies the potential of IL - 6 level as a prognostic marker for the severity of COVID - 19. In addition, the study also emphasizes the influence of variants on inflammatory markers, providing important data support for further understanding the pathological mechanism of COVID - 19.